Novo Nordisk's deal with Korro is worth a total of $530 million in research and development (R&D) funding, milestone payments ...

RBC Capital analyst Luca Issi maintained a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of $95.00. The ...

Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on Korro Bio (KRRO – Research Report) and keeping the price target at ...

Novo Nordisk isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two ...

Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform ...

Cambridge, USA-based Korro Bio has entered a collaboration with Denmark’s Novo Nordisk to advance the discovery and ...

Sept. 16, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a potential new class of genetic medicines based on RNA editing for both ...

Korro Bio Inc. has established a collaboration with Novo Nordisk A/S to advance the discovery and development of new genetic medicines, initially to treat cardiometabolic diseases. The collaboration ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CAMBRIDGE, Mass. - Korro Bio, Inc. (NASDAQ:KRRO), a biopharmaceutical company, has announced a strategic collaboration with global healthcare company Novo Nordisk (NYSE:NVO) to develop new genetic ...

CAMBRIDGE, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a potential new class of genetic medicines based on ...